Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 28, 2015
Eisai Inc. announced today the U.S. Food and Drug Administration (FDA) granted lenvatinib, the company's multiple receptor tyrosine kinase inhibitor, Breakthrough Therapy designation for the...
- Jul 16, 2015Deal Supports Strategic Directions of Both Companies and Expands Collaboration
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has entered into a definitive agreement to transfer ownership of its Research Triangle Park (RTP)...
-
Jun 22, 2015New Indication Provides a Treatment Option for Epilepsy Patients Who Suffer from PGTC Seizures that are not Adequately Controlled with Current Treatment
Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA® (perampanel) CIII for adjunctive therapy in the treatment of primary generalized tonic-clonic...
- Jun 1, 2015
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Ivor Macleod to the position of Senior Vice President, Chief Financial Officer (CFO)...
-
Jun 1, 2015Lenvatinib, investigated in patients with metastatic renal cancer, showed an increase in progression-free survival (PFS)
Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival...
-
May 30, 2015Data from pivotal study for eribulin to be presented during oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting
Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced...
-
May 14, 2015Company demonstrates dedication to rare cancers
Eisai Inc. announced today the presentation of seven abstracts at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) highlighting the breadth of the company's oncology...
-
Apr 30, 2015
Eisai Inc. and Eisai Co., Ltd. have entered into a settlement agreement with Glenmark Pharmaceuticals, Ltd., Glenmark Generics Ltd., and Glenmark Generics, Inc., USA ("Glenmark"), to resolve their...
-
Apr 15, 2015
Helsinn Group and Eisai Inc. jointly announced today the decision of the National Comprehensive Cancer Network (NCCN) to include AKYNZEO® in the 2015 NCCN Antiemesis Guidelines as a recommended...
- Apr 13, 2015-- Data to Highlight Impact of H3's Splicing Modulation Platform --
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology, announced today that it will present a series of posters at the...
-
Apr 10, 2015-- New Drug Application for once-daily formulation of lorcaserin expected to be submitted to the FDA later this year --
WOODCLIFF LAKE, NJ, and SAN DIEGO, CA, April 10, 2015 – Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of two Phase 1 registrational clinical trials...
-
Apr 9, 2015
Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., today announced plans to realign its operations in the United States. As part of this restructuring, Eisai Inc. will reduce its workforce by...
-
Mar 30, 2015Clinical Study (003-011) to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD)
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has enrolled the first patient in a randomized, double-blind study of farletuzumab in first-relapsed, platinum-sensitive...
- Feb 27, 2015A New Drug Approved for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Eisai Inc. announced today that LENVIMA™ (lenvatinib), a receptor tyrosine kinase inhibitor, is now available through two specialty pharmacies, Accredo and Biologics, Inc. LENVIMA is indicated...
-
Feb 25, 2015Eisai Demonstrates Commitment to Patients with Rare Cancers
Eisai Inc. today announced that eribulin met the primary endpoint in its Phase 3 trial (Study 309), demonstrating a statistically significant improvement in overall survival (OS) in patients with...
-
Feb 19, 2015
Eisai Inc. today announced the launch of BELVIQ VOICES, an online community featuring real life weight loss journeys of patients living with obesity. Meant to inspire and encourage honest, open...
-
Feb 13, 2015- New Therapy Demonstrated a Dramatic Improvement in Progression-Free Survival and a Statistically Significant Overall Response Rate in Some Patients with RAI-Refractory Differentiated Thyroid Cancer
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the company's receptor tyrosine kinase inhibitor LENVIMA™ (lenvatinib) for the treatment of locally recurrent...
- Feb 13, 2015
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for BANZEL® (rufinamide) as an adjunctive treatment of seizures...
-
Feb 12, 2015FOR U.S. MEDIA ONLY
Results from the pivotal Phase 3 SELECT (Study of (E7080) LEnvatinib in Differentiated Cancer of the Thyroid) trial evaluating the use of investigational agent lenvatinib in the treatment of...
- Jan 20, 2015Eisai Launches New Savings Card to Increase Access and Affordability of BELVIQ® (lorcaserin HCl) CIVCard Enables Eligible Patients to Pay No More than $75 for their BELVIQ Prescription*
Eisai Inc. today announced the launch of a new savings card for BELVIQ® (lorcaserin HCl) CIV, the most prescribed branded FDA-approved prescription drug therapy for chronic weight management.**...
-
Jan 15, 2015•The European Prevention of Alzheimer’s dementia (EPAD) Initiative is a collaborative research initiative to improve the chance of successfully preventing Alzheimer’s dementia and to better understand early aspects of Alzheimer’s disease before dementia develops.
Paris, January 15, 2015 – The members of the EPAD initiative today announced the start of a novel collaboration between academic and private sectors to test innovative treatments for the...
- Dec 5, 2014-- Results of Investigational Studies of Perampanel and Rufinamide Accepted as Late-Breaking Posters --
Eisai Inc. announced today that 16 abstracts highlighting new data on perampanel and rufinamide will be presented at the 68th Annual American Epilepsy Society (AES) meeting, taking place in...
-
Dec 1, 2014FOR U.S. MEDIA ONLY
Eisai announced the presentation of six abstracts at the 2014 San Antonio Breast Cancer Symposium (SABCS), highlighting new data for eribulin mesylate and netupitant/palonosetron (NEPA). The...
-
Nov 17, 2014
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that Eisai has been ranked 11th among the world's leading pharmaceutical companies in the Access to Medicine Index...
- Nov 6, 2014Celebrity Animal Behaviorist Brandon McMillan Joins Eisai, Epilepsy Foundation and 4 Paws for Ability to Shed Light on How Dogs Can Provide Functional and Emotional Support
Eisai Inc. today announced the launch of Magnolia™ Paws for Compassion™, a new program created to raise awareness of the beneficial impact that animals can have on people living with epilepsy...
-
Nov 6, 2014-- Lorcaserin Evaluated for Effect on the NASH Clinical Score: A Retrospective Analysis of Three Phase 3 Studies --
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for lorcaserin HCl will be presented at the Annual Meeting of the...
-
Nov 3, 2014-- Trial Met Primary Efficacy Endpoint with Statistical Significance After 12 Weeks of Treatment --
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results from the Phase 2 trial investigating lorcaserin HCl, a serotonin 2C receptor agonist, for smoking...
-
Oct 31, 2014-- Results of Investigational Study of Coadministration of Lorcaserin and Phentermine Accepted as Late Breaking Poster --
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data for BELVIQ® (lorcaserin HCl) CIV will be presented during ObesityWeekSM hosted by The Obesity Society and the...
-
Oct 28, 2014-- Trial Met Primary Safety Objective After 12 Weeks of Treatment -- -- Data to be Presented at The Obesity Society 2014 Annual Meeting During ObesityWeekSM --
WOODCLIFF LAKE, NJ and SAN DIEGO, CA, October 28, 2014 – Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results of a pilot study to assess the safety of...
- Oct 20, 2014
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company's Supplemental New Drug Application (sNDA) for its in-house-discovered AMPA receptor...
- Oct 14, 2014
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's sNDA for rufinamide and granted it priority review designation as an adjunctive treatment of...
-
Oct 14, 2014
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its in-house developed agent lenvatinib mesylate (lenvatinib)...
Oct 13, 2014Recognizing unique patient needs on Metastatic Breast Cancer Awareness Day, mbcInfoCenter.com offers important metastatic breast cancer resources in one convenient placeWoodcliff Lake, NJ, October 13, 2014 / PR Newswire / — Understanding the burden of metastatic breast cancer (MBC), and the toll it takes on patients and their loved ones, Eisai Inc....
-
Oct 13, 2014
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the American...
-
Oct 13, 2014-- First New Fixed Combination Targeting Two Critical Pathways Involved in CINV --
Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and...
- Oct 10, 2014
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a pooled analysis of the BLOOM and BLOSSOM pivotal, Phase 3 clinical trials of BELVIQ® (lorcaserin HCl) was...
- Oct 1, 2014Findings suggest need for improved education efforts within epilepsy community and beyond to address misperceptions about the disease
Results from a national survey conducted by Eisai Inc., in partnership with the Epilepsy Foundation, found that the vast majority (95%) of epilepsy patients and caregivers believe the public is...
-
Sep 10, 2014
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the American...
- Sep 3, 2014
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has entered into an agreement with Concordia Pharmaceuticals Inc. ("Concordia"), a subsidiary of Concordia...
- Jun 26, 2014
Eisai Inc. and Helsinn Group announced today that several abstracts highlighting data analyses of NEPA, an investigational oral fixed-dose combination of netupitant and palonosetron being...
- Jun 23, 2014Those Who Take Steps Report Greater Satisfaction with Weight Loss Medications and Surgical Procedures
An analysis of data from the 2012 U.S. National Health and Wellness Survey showed that the majority of those affected by obesity are not taking steps to lose weight (58.4%). The analysis of more...
- Jun 23, 2014
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Barry Lederman to the position of Vice President and Chief Financial Officer (CFO)....
- Jun 16, 2014
Eisai Inc. announced today that a Phase III clinical trial (study 332) of its in-house-discovered AMPA receptor antagonist perampanel has met its primary endpoint in patients with primary...
- Jun 13, 2014Pre-Game Activities Honor Local Epilepsy Awareness Ambassadors
Eisai Inc. announced today it has become a "Keeper of the Flame" sponsor of the Epilepsy Foundation of Metropolitan New York's 2nd Annual Epilepsy Awareness Day which will take place during a...
- Jun 9, 2014
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the American...
-
May 31, 2014Phase III data for lenvatinib to be presented at ASCO
Eisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive...
- May 28, 2014-- Pediatric Patients Aged 1 Month to Less Than 17 Years Now Have A New Option to Help Prevent Acute Chemotherapy-Induced Nausea and Vomiting --
Eisai Inc. and Helsinn Group today announced the Food and Drug Administration (FDA) approval of ALOXI® (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with...
- May 22, 2014- Companies Advance Multiple Co-discovery Programs for First-in-class Targets in Oncology -
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and Selvita (PL: SLV), one of the largest drug discovery companies...
- May 15, 2014Obesity Education Network Provides Tools to Help Physicians Assess and Manage Patients Who are Overweight or Obese
Eisai Inc. today announced the launch of a website that will provide physicians with access to comprehensive clinical information that addresses obesity screening and risk assessment,...
-
May 14, 2014Data underscore breadth of oncology portfolio
Eisai Inc. announced today that 10 abstracts highlighting new study results will be presented during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in...
- May 9, 2014Expansion Enables Eisai to Reach 90,000 Healthcare Providers
Eisai Inc. announced today it will add more than 200 new contract sales representatives to its Metabolic Business Unit, bringing the total sales force for BELVIQ® to approximately 600, triple the...
- Apr 29, 2014-- Doctors Can Help Patients Set Personal Weight Loss Goals: It's Not a One Size Fits All Approach --
Eisai Inc. today announced the launch of My Healthy™, an interactive and motivational campaign that shifts the focus of the obesity conversation away from just pounds lost to health gained....
- Apr 25, 2014
Eisai Inc. announced today that six abstracts highlighting data analyses for FYCOMPA™ (perampanel) will be presented at the 66th annual American Academy of Neurology (AAN) meeting, taking place...
-
Apr 14, 2014- Campaign Creates Awareness of Prescription Drug Option for Chronic Weight Management -
Eisai Inc. today announced the launch of a new national television advertising campaign for BELVIQ® (lorcaserin HCl) CIV, an FDA-approved prescription therapy
- Apr 3, 2014- Company to Present Data on SF3B1 Program at a Symposium During the American Association for Cancer Research Annual Meeting 2014 -
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology, announced today...
-
Mar 31, 2014
Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the sale and assignment of its rights to a worldwide exclusive license...
-
Mar 20, 2014JOINT RESEARCH PROJECT AWARDED GHIT FUND GRANT
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has entered a collaboration with the Liverpool School...
-
Mar 17, 2014Eisai Supports Epilepsy Foundation as Sponsor of Walk
Eisai Inc. announced today that it is a sponsor of the Epilepsy Foundation's 8th Annual National Walk for Epilepsy in Washington D.C., a...
-
Mar 13, 2014Sisters Network® Inc. launches innovative pilot program designed to help address breast cancer disparities affecting the African American community
Sisters Network, the only national African American breast cancer survivorship organization, announced today the launch of Teens 4...
-
Mar 10, 2014Company Appoints New Executive Leaders
Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the appointments of Yuji Matsue as chairman and chief executive...
-
Feb 27, 2014Patient Recruitment Now Underway at Treatment Centers Across the United States
Eisai Inc. today announced the start of a large, randomized Phase 3 trial to compare the efficacy, safety and tolerability of eribulin mesylate...
-
Feb 24, 2014Patient Recruitment and Enrollment Now Underway
Eisai Inc. today announced that patient recruitment and enrollment are currently underway for CAMELLIA-TIMI 61, a randomized double-blind,...
-
Feb 12, 2014
Eisai Inc. announced today that its subsidiary Eisai Laboratorios Ltda has filed for the marketing authorization of BELVIQ as a treatment for...
-
Feb 10, 2014Number of Insured Commercial Lives in the U.S. with Coverage for BELVIQ® Now Exceeds 50 Percent
Eisai Inc. reported today that it has secured improved patient access of BELVIQ® (lorcaserin HCl) with two leading healthcare benefit...
-
Feb 2, 2014
Eisai Inc. announced today that the Phase 3 SELECT trial (Study 303) of investigational agent lenvatinib met its primary endpoint. Compared to...
-
Jan 2, 2014FYCOMPA is the First and Only FDA-Approved Non-Competitive AMPA Glutamate Receptor Antagonist
Eisai Inc. announced today that FYCOMPA™ (perampanel) CIII will be available to eligible patients by prescription in the U.S. beginning...
-
Dec 9, 2013Seeking indication for prevention of chemotherapy-induced nausea and vomiting
Helsinn Group and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted for review the...
-
Dec 5, 2013
Today, Eisai Inc. announced that 16 abstracts highlighting new data analyses on FYCOMPA (perampanel) will be presented at the 67th annual...
-
Dec 4, 2013
Eisai Inc. announced today that five abstracts highlighting new study results will be presented during the 2013 San Antonio Breast Cancer...
-
Dec 3, 2013Eisai Tackles Stigma Associated With Epilepsy Through Support Of Comic Book Addressing The Condition"Medikidz Explain Epilepsy" Aims to Help Children Better Understand the Disease
Eisai Inc., a leader in the epilepsy community, is proud to announce the availability of a first-of-its-kind comic book in the U.S. designed to...
-
Nov 25, 2013
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has become a signatory to the Tuberculosis Drug...
-
Nov 18, 2013Representatives Will Use Educational Tool for Up to 65,000 Physicians
Eisai and BusinessOne Technologies announced today that Eisai Inc. is using the Maestro Market Access Mobile™ application...
-
Nov 13, 2013BELVIQ® (lorcaserin HCl) CIV Data Featured in Five Abstracts to be Presented at ObesityWeek(SM) 2013
Eisai Inc. and Arena Pharmaceuticals, Inc., (NASDAQ:ARNA) announced today that five abstracts highlighting new data analyses from...
-
Nov 13, 2013Eisai to Convene Multidisciplinary Expert Panel in an Effort to Combat Growing Epidemic
A new survey conducted by Eisai Inc., in partnership with the Obesity Action Coalition (OAC) and The Obesity Society (TOS), reveals a...
-
Nov 8, 2013
Eisai Inc. announced today that ACIPHEX® Sprinkle™ Delayed-Release Capsules 5mg and 10mg will be available to eligible patients by...
-
Nov 7, 2013-- Collaboration to Focus on Global Commercialization and Development for Weight Management and Potential New Indications --
SAN DIEGO, CA and WOODCLIFF LAKE, NJ, November 7, 2013 – Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the BELVIQ® (lorcaserin HCl) marketing...
-
Nov 1, 2013Award supports vital research to understand rare and severe form of epilepsy
The Child Neurology Foundation (CNF) and Eisai Inc. today announced that the first annual Michael SanInocencio Lennox-Gastaut Syndrome (LGS)...
-
Oct 28, 2013FIRST SHIPMENT TO BENEFIT MORE THAN 6 MILLION PEOPLE IN 4 ENDEMIC COUNTRIES
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has begun the free supply of...
-
Oct 15, 2013BELVIQ® Sales Force to Double in Size by December 2013
Eisai Inc. announced today that, as part of its long-term marketing strategy, the company will expand its sales force by adding more than 200...
-
Oct 9, 2013Cornucopia Cancer Support Center™ Joins Forces with the Eisai Women’s Oncology Program - Magnolia™, CancerCare®, Cancer Support Community(SM) and Meals On Wheels Association of America™ to Help Ease the Stress of Those Living with Breast Cancer
Woodcliff Lake, NJ, October 7, 2013- Magnolia Meals at HomeTM, a program that delivers nutritious meals at no-cost to patients living with breast cancer and their families, is now available in...
-
Oct 9, 2013
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the Children's Oncology Group (COG) has opened enrollment in a Phase 1 clinical study...
-
Oct 1, 2013Eisai, CancerCare®, and Cancer Support Community(SM) Launch meal Trains(SM) sponsored by Magnolia™ During Breast Cancer Awareness Month; Campaign Aims to Drive 1,000 New meal Trains in October
Eisai Inc., along with collaborators CancerCare and Cancer Support Community, have announced meal TrainsSM sponsored by Magnolia™, which aim...
-
Sep 16, 2013- Companies Initiate Multiple Co-discovery Programs for First-in-class Targets in Oncology -
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision oncology...
-
Sep 12, 2013Eisai Launches BELVIQ® Patient Support Program Offering On-Line Tools to Enhance Weight Loss EffortsThe BELIEVE EVERYDAY SUPPORTSM Program Offers Customized Lifestyle Resources and Free Membership to Top Calorie Tracking App for Use by BELVIQ® (lorcaserin HCl) CIV Patients
Eisai Inc. today announced the availability of the BELIEVE EVERYDAY SUPPORTSM program to provide free, comprehensive support and savings for BELVIQ
-
Aug 29, 2013
Eisai Inc. announced that the company has recently entered into a non-exclusive licensing agreement in the United States with a manufacturer of...
-
Aug 19, 2013Epilepsy Drug Still Not Available to Patients 10 Months After FDA Approval
Eisai Inc. filed a petition today with the U.S. Court of Appeals for the District of Columbia asking the court to direct the Drug Enforcement...
-
Aug 15, 2013
Eisai Inc. announced today the launch of a new website to provide employers with an educational resource for information about obesity...
-
Aug 8, 2013
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational compound...
-
Jul 8, 2013The Eisai Women’s Oncology Program - MagnoliaTM, CancerCare®, Cancer Support CommunitySM and Meals On Wheels Association of AmericaTM Are Working Together to Help Ease the Stress of Those Living with Breast Cancer in New Jersey
Woodcliff Lake, NJ, July 8, 2013- Magnolia Meals at Home™, a program that delivers nutritious meals at no-cost to patients living with breast cancer and their families, is now available in Essex...
-
Jul 3, 2013Earns V2.2 Gold Certification for New Construction
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has achieved LEED® certification for its new 60,000-square-foot pilot plant...
-
Jun 20, 2013
Eisai Inc. and Arena Pharmaceuticals, Inc., (NASDAQ:ARNA) announced today that data from the BELVIQ® (lorcaserin HCl) Phase 3...
-
Jun 14, 2013
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), announced today that data from the BELVIQ® (lorcaserin HCl) Phase 3...
-
Jun 13, 2013Former Secretary of State and Epilepsy Advocate Hillary Rodham Clinton to Speak as This Year's Guest of Honor
Eisai Inc. announced today its platinum level sponsorship of the Citizens United for Research in Epilepsy (CURE) 15th Annual Chicago Benefit...
Jun 7, 2013BELVIQ Available in U.S. Pharmacies within One WeekWOODCLIFF LAKE, NJ, June 7, 2013 /PRNewswire/ — Eisai Inc. announced today that BELVIQ (pronounced BEL-VEEK) will be available to eligible patients by prescription in the United States...
-
May 16, 2013
Eisai Inc. announced today that nine abstracts highlighting new study results in melanoma, breast and endometrial cancer will be presented during...
-
May 16, 2013Will Lead Commercial Strategy for Eisai's Subsidiary in Mexico
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the appointment of Ricardo Gonzalez Balboa to the position of...
-
May 16, 2013Data to Be Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)
Helsinn Group and Eisai Inc. announced today top-line results from Helsinn's pivotal clinical studies investigating the...
-
May 9, 2013
Eisai USA Foundation Inc., the charitable arm of Eisai Inc., announces that it has pledged a $1 million donation to the Conquer Cancer Foundation...
-
May 8, 2013
Eisai Inc. announced today that the U.S. Drug Enforcement Administration (DEA) has placed BELVIQ (pronounced BEL-VEEK) into Schedule IV of the...
-
Apr 18, 2013-- 4 Paws for Ability Service Dogs to Greet Visitors at Eisai Event Booth --
Woodcliff Lake, NJ - April 18, 2013 - Eisai Inc. announced today that it is a silver level sponsor of the Epilepsy Foundation's 7th Annual National Walk for Epilepsy, a family-oriented,...
